DLA Piper advised Alimera Sciences, Inc., a global pharmaceutical company focused on ophthalmic solutions, in its acquisition by ANI Pharmaceuticals, a diversified biopharmaceutical company, in a transaction that values Alimera at approximately US$381 million in up front consideration plus contingent value rights providing for additional consideration upon the achievement of certain revenue milestones. The transaction is subject to customary closing conditions, including receipt of required regulatory approvals and approval by Alimera’s shareholders.
Alimera is a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with maintaining better vision longer. Alimera’s two commercial products, ILUVIEN® and YUTIQ®, treat diabetic macular edema (DME) and chronic non-infectious uveitis affecting the posterior segment (NIU-PS) of the eye.
ANI is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need.
“It was a pleasure advising Alimera with our industry-specific insights and our extensive M&A experience on this significant acquisition.” said Andrew Gilbert, US chair of the Corporate practice and the DLA Piper partner who led the deal team.
In addition to Gilbert, the DLA Piper team was co-led by Jeffrey Scharfstein and Scott Cowan and included partners Brian Hamano, Rita Patel, Georgia Jolink, Jeff Aronson, Heather Water Borthwick and Paolo Morante, and associates Victoria McGuire, Vincent Schiavoni and Jessica Stenglein.
“We greatly value the transactional and industry experience of our DLA Piper team as well as their tireless attention to client service”, said Rick Eiswirth, CEO of Alimera.
With more than 1,000 corporate lawyers globally, DLA Piper helps clients execute complex transactions seamlessly while supporting clients across all stages of development. The firm has been rated number one in global M&A volume for 14 consecutive years, according to Mergermarket.
DLA Piper’s globally recognized life sciences team has spent decades helping entrepreneurs, companies, innovators, and investors turn their most promising and disruptive ideas into successful businesses. Drawing on diverse backgrounds in the legal, financial, and medical sectors and beyond, our team brings a distinctive blend of experience to develop client-focused solutions. We understand the unique challenges life science companies face in securing funding, licensing and safeguarding intellectual property, establishing partnerships, bringing new products to market, opening new paths to profitability, and protecting existing innovation. Our approach delivers both strategic and practical counsel to clients, ultimately leading to better human outcomes.
Original source can be found here.